Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Satralizumab (Enspryng), a humanized monoclonal antibody, is specifically designed to target and inhibit the interleukin-6 (IL-6) receptor. Interleukin-6 receptor alpha (IL-6Ra or CD126) is a critical component of the IL-6 signaling pathway, which plays a pivotal role in immune regulation, inflammation, and hematopoiesis. The gene for IL-6Ra is located on chromosome 1 at the p31 region. The structure of IL-6Ra includes an extracellular domain that binds IL-6, a transmembrane domain, and an intracellular domain that interacts with the signal transducer gp130, facilitating the activation of downstream signaling pathways. There are two forms of IL-6 signaling: classic signaling, which occurs when membrane-bound IL-6Ra (mIL-6Ra) forms a complex with IL-6 and gp130, primarily affecting immune cells and hepatocytes; and trans-signaling, which involves a soluble form of IL-6Ra (sIL-6Ra) and can act on a broader range of cells. Dysregulation of IL-6 and its receptor has been implicated in various inflammatory and autoimmune diseases, making them targets for therapeutic intervention.
仅用于科研。不用于诊断过程。未经明确授权不得转售。